Abstract
In the present study, I explore the link between COVID-19 vaccine patents and their financialization within the institutional economics framework. Thorstein Veblen’s main assumptions related to financialization of intangible assets are valid for the pharmaceutical firms that produced COVID-19 vaccines during the pandemic. In this context, the effects of patent applications on the financialization of pharmaceutical firms are investigated for companies that took government grants for vaccine production. These firms are examined in a comparative way in the present study. The market figures, the investigation of the relevant firm-level data, and the institutional setting suggest that the COVID-19 vaccine patents-financialization nexus is well defined in the Veblenian framework during the pandemic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
